Tyra Biosciences, Inc. Shareholders' Equity
Tyra Biosciences, Inc. (TYRA) had Shareholders' Equity of $353.66 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-04
- 2026-06-30: Stockholders' Equity Attributable to Parent $353.66M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $387.57M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $259.18M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $280.51M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $353.66M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $387.57M 10-Q · filed 2026-08-04 |
| 2025-12-31 | $259.18M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $280.51M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $302.15M 10-Q · filed 2026-08-04 |
| 2025-03-31 | $323.53M 10-Q · filed 2026-08-04 |
| 2024-12-31 | $343.15M 10-Q · filed 2026-08-04 |
| 2024-09-30 | $362.29M 10-Q · filed 2025-11-05 |
| 2024-06-30 | $376.04M 10-Q · filed 2025-11-05 |
| 2024-03-31 | $389.88M 10-Q · filed 2025-11-05 |
| 2023-12-31 | $204.26M 10-K · filed 2026-03-02 |
| 2023-09-30 | $222.17M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $238.57M 10-Q · filed 2024-11-07 |
| 2023-03-31 | $248.79M 10-Q · filed 2024-11-07 |
| 2022-12-31 | $257.83M 10-K · filed 2025-03-27 |
| 2022-09-30 | $267.76M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $278.85M 10-Q · filed 2023-11-07 |
| 2022-03-31 | $291.18M 10-Q · filed 2023-11-07 |
| 2021-12-31 | $301.74M 10-K · filed 2024-03-19 |
| 2021-09-30 | $309.73M 10-Q · filed 2022-11-03 |
| 2021-06-30 | -$22.67M 10-Q · filed 2022-11-03 |
| 2021-03-31 | -$17.52M 10-Q · filed 2022-11-03 |
| 2020-12-31 | -$13.64M 10-K · filed 2023-03-22 |
| 2020-09-30 | -$10.08M 10-Q · filed 2021-11-03 |
| 2020-06-30 | -$7.85M 10-Q · filed 2021-11-03 |
| 2020-03-31 | -$6.11M 10-Q · filed 2021-11-03 |
| 2019-12-31 | -$4.74M 10-K · filed 2022-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |